The study of the assortment of drugs of acetylsalicylic acid in combination with statin

O. V. Tryhubchak

Abstract


Aim. To analyze the world pharmaceutical market of combined drugs of acetylsalicylic acid with statin.

Materials and methods. The study was conducted on the basis of the lists of medicines registered in 28 countries of the European Union, Liechtenstein, Norway, Switzerland, the Commonwealth of Independent States (Ukraine, Belarus, Russian Federation, Kazakhstan), Egypt, Morocco, Syria, India, Australia, Canada, the USA and the African continent. The methods of scientific analysis, in particular methods of grouping and comparison, marketing research were used in this work analysis, synthesis and comparison.

Results. Combined drugs of acetylsalicylic acid with statin are registered in Ukraine, Austria, Spain, India, Portugal, Slovenia, France and the United States. They differ in trade names and contain different active pharmaceutical ingredients (APIs) from the group of statins in different doses. Some medicines are additionally combined with antihypertensive drugs. The largest number of combined drugs of acetylsalicylic acid with atorvastatin has been registered in India. They are produced by the Indian manufacturers in the form of capsules (17 drugs) and tablets (14 drugs) for 10 pieces in a pack. The composition of 64.52 % of the drugs includes 75 mg of acetylsalicylic acid and 10 mg of atorvastatin. The ratio of APIs of 150 mg / 10 mg occurs 8 times, and only 3 drugs has the ratio of 150 mg / 20 mg.


Conclusions. The results of the marketing research have allowed us to analyze the structure of the range of drugs of acetylsalicylic acid with statins registered in Ukraine, Austria, Spain, India, Portugal, Slovenia, France and the USA. Substances from the group of statins combined with acetylsalicylic acid have been found. The study of the assortment of drugs of acetylsalicylic acid with atorvastatin at the Indian market has been conducted.


Keywords


combined drugs; market analysis; tablets; acetylsalicylic acid; statins

References


1.Udell, J. A., Scirica, B. M., Braunwald, E., Raz, I., Gabriel Steg, P., Davidson, J., ... Bhatt, D. L. (2012). Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clinical cardiology, 35 (12), 722-729. doi: 10.1002/clc.22032.

2.Bahiru, E., de Cates, A. N., Farr, M. R., Jarvis, M. C., Palla, M., Rees, K., ... Huffman, M. D. (2017). Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev, 3, CD009868. doi: 10.1002/14651858.

3.De Berardis, G., Sacco, M., Evangelista, V., Filippi, A., Giorda, C. B., Tognoni, G., ... Nicolucci, A. (2007). Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials, 8 (1), 21. doi: 10.1186/1745-6215-8-21.

4.Lafeber, M., Spiering, W., Visseren, F. L., Grobbee, D. E., Bots, M. L., Stanton, A., ... Rodgers, A. (2017). Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk: The influence of baseline medication on LDL-cholesterol, blood pressure and calculated risk reduction when switching to a cardiovascular polypill. European journal of preventive cardiology, 24 (9), 951-961. doi: 10.1177/2047487317695616.

5.Lafeber, M., Spiering, W., van der Graaf, Y., Nathoe, H., Bots, M. L., Grobbee, D. E., Visseren, F. L. (2013). The combined use of aspirin, a statin, and blood pressure–lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. American heart journal, 166 (2), 282-289. doi: 10.1016/j.ahj.2013.04.011.

6.Working Group on the Summit on Combination Therapy for CVD. (2013). Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. European Heart Journal, 7 (35 (6)), 353-364. doi: 10.1093/eurheartj/eht407.

7.Trygubchak, O. V., Voytkova, L. S. (2015). Trend Analysis of Combined Drugs Creation (for Example Acetylsalicylic Acid). Journal of Pharmacy and Pharmacology, 10 (3 (23)), 451-462. doi: 10.17265/2328-2150/2015.10.002.

8.Trygubchak, O. V., Hroshovyi, T. A. (2016). Proceeding from Naukovo-tekhnichnyi prohres i optymizatsiia tekhnolohichnykh protsesiv stvorennia likarskykh preparativ: materialy VI naukovo-praktychnoi konferentsii z mizhnarodnoiu uchastiu (November 10-11, 2016) (pp. 254-255).Ternopil: Ukrmedknyha.

9.Atorvastatin with aspirin (2007-2018). Medline India. Available at: http://www.medlineindia.com/cardiovascular/atorvastatin_with_aspirin.htm


GOST Style Citations


1.Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus / Jacob A. Udell [et al.] // Clinical cardiology. – 2012. – Vol. 35, Issue 12. – P. 722-729. doi : 10.1002/clc.22032.

2.Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases / E. Bahiru [et al.] // Cochrane Database Syst Rev. – 2017. – Vol. 3. – P. CD009868. doi : 10.1002/14651858.

3.Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins / Giorgia De Berardis [et al.] // Trials. – 2007. – Vol. 8, Issue 21. – P. 1-9. doi : 10.1186/1745-6215-8-21.

4.Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk / M. Lafeber [et al.] // Eur J Prev Cardiol. – 2017. – Vol. 24, Issue 9. – P. 951-961. doi : 10.1177/2047487317695616.

5.The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease / M. Lafeber [et al.] // Am Heart J. – 2013. – Vol. 166, Issue 2. – P. 282-289. doi : 10.1016/j.ahj.2013.04.011.

6.Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges / Working Group on the Summit on Combination Therapy for CVD // European Heart Journal. – 2014. – Vol. 7, Issue 35, No. 6. – P. 353-364. doi : 10.1093/eurheartj/eht407.

7.Trygubchak, O. V. Trend Analysis of Combined Drugs Creation (for example Acetylsalicylic Acid) / O. V. Trygubchak, L. S.Voytkova // Journal of Pharmacy and Pharmacology. – 2015. – Vol. 10, Issue 3, Serial Number 23. – P. 451-462. doi : 10.17265/2328-2150/2015.10.002.

8.Тригубчак, О. В. Маркетингові та фармакоекономічні дослідження препаратів ацетилсаліцилової кислоти з статинами / О. В. Тригубчак, Т. А. Грошовий // Науково-технічний прогрес і оптимізація технологічних процесів створення лікарських препаратів : матеріали VI наук.-практ. конф. з міжнар. участю, м. Тернопіль, 10-11 листоп. 2016. – Тернопіль, 2016. – С. 254-255.

9.Medline India. Atorvastatin with aspirin [Internet]. Medline India; 2007-2018 [cited 2015-2018]. Available at : http://www.medlineindia.com/cardiovascular/atorvastatin_with_aspirin.htm






DOI: https://doi.org/10.24959/sphhcj.18.127

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Soc. farm. ohor. zdor.

ISSN 2518-1564 (Online), ISSN 2413-6085 (Print)